First Derivatives CEO diagnosed with cancer
The CEO of Newry-based First Derivatives, Brian Conlon, has been diagnosed with cancer.
Mr Conlon will remain as CEO during his ongoing weekly treatment, which includes chemotherapy. This treatment is expected to last a number of months, the group said in a statement.
Seamus Keating, chairman of First Derivatives, will provide additional executive and governance support while Mr Conlon is receiving care.
"The board has set a clear strategy and the Executive Committee, led by Brian, has delivered strong execution of that strategy year-on-year,” Mr Keating said.
“During the period of his treatment I will provide additional executive and governance support and I am confident that Brian and his team will continue to execute the group's growth plans successfully."
First Derivatives operates from 14 offices across Europe, North America and Asia Pacific, including its headquarters in Newry, and employs more than 2,600 people worldwide.